Eluminex Biosciences Completes Series B+ Financing, Raising More Than $50 M in 2023

  • Provides Additional Resources for First-in-Class Recombinant Human Collagen Program in Regenerative Medicine
  • Enables First-in-Human Clinical Entry of Novel Multivalent Proteins for Retinal Diseases in 2024

August 18, 2023, Suzhou, China/San Francisco, USA – Eluminex Biosciences (Suzhou) Limited (Eluminex) announces that following completion of a $40 million (USD) Series B financing in February 2023, it successfully completed an additional B+ round of financing from Oriza FOFs and Suxin Venture Capital Investment. In total, Eluminex has raised more than $50 million (USD) in venture capital this year to rapidly advance multiple preclinical and clinical programs.

Eluminex is a clinical-stage biotechnology company dedicated to the research and development of global innovative therapeutics with a major focus in ophthalmology and tissue regeneration based upon recombinant human collagen. The company intends to use the funding to accelerate its capabilities in recombinant human collagen manufacturing and development of programs in regenerative medicine and further advance a new class of multivalent proteins for the treatment of vision-threatening diseases.

Dr. Jinzhong Zhang, Founder, Chairman and Chief Executive Officer of Eluminex Biosciences, stated “we are extremely grateful to the support Eluminex has received from both the new investors and existing venture partners for their recognition and support of the company and its mission. The proceeds put the company on solid footing to push forward our scientific agenda of developing first-in-class/best-in-class therapeutics for unmet needs in ophthalmology and regenerative medicine for the global marketplace.”

In ophthalmology, Eluminex is developing multiple next-generation anti-VEGF multivalent biomacromolecules for the treatment of age- and diabetes-related retinal diseases as well as other retinal vascular diseases and is targeting clinical entry in the United States in 2024 for its first multivalent program.

In tissue regeneration, Eluminex seeks to become the world’s leader in recombinant human collagen technology. The company has developed the capability to express and manufacture full-length type III human collagen (rhCIII) with triple helix structure through synthetic biology and is currently establishing an industrial facility to produce commercial scale of rhCIII. Recombinant human collagen with triple helical structure has wide applications in tissue repair and regeneration including development of a biosynthetic cornea as an alternative to human allografts.

Eluminex Biosciences headquarters and research and development center are located in BioBAY of Suzhou Industrial Park, China, with a clinical and registration center located in the San Francisco Bay Area in California.


Contact for Investors/Media: